The patient was administered with routine anti-mycobacterial regimen in addition to adjuvant IFN-γ therapy that can restore macrophage function and provide a better control of BCG-osis in MSMD patients, particularly in patients with IL-12Rβ1 deficiency [14]. The gene discussed is IFNG; the disease is Mendelian susceptibility to mycobacterial diseases.